Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Xencor stock
Learn how to easily invest in Xencor stock.
Xencor Inc is a biotechnology business based in the US. Xencor shares (XNCR) are listed on the NASDAQ and all prices are listed in US Dollars. Xencor employs 254 staff and has a trailing 12-month revenue of around $289.4 million.
How to buy shares in Xencor
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – XNCR – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Xencor stock price (NASDAQ: XNCR)Use our graph to track the performance of XNCR stocks over time.
Xencor shares at a glance
|Latest market close||$25.83|
|52-week range||$19.36 - $43.61|
|50-day moving average||$28.04|
|200-day moving average||$29.17|
|Wall St. target price||$48.25|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$0.37|
Buy Xencor shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Xencor stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Xencor price performance over time
|1 week (2022-09-27)||3.20%|
|1 month (2022-09-02)||-2.71%|
|3 months (2022-07-01)||-10.50%|
|6 months (2022-04-04)||-10.96%|
|1 year (2021-10-04)||-27.28%|
|2 years (2020-10-02)||-29.48%|
|3 years (2019-10-04)||35.39|
|5 years (2017-10-04)||4.03%|
Is Xencor stock undervalued or overvalued?
Valuing Xencor stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Xencor's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Xencor's P/E ratio
Xencor's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 70x. In other words, Xencor shares trade at around 70x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Xencor's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $58.3 million.
The EBITDA is a measure of a Xencor's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$289.4 million|
|Operating margin TTM||17.19%|
|Gross profit TTM||$82.6 million|
|Return on assets TTM||4.02%|
|Return on equity TTM||3.24%|
|Market capitalisation||$1.6 billion|
TTM: trailing 12 months
Xencor share dividends
We're not expecting Xencor to pay a dividend over the next 12 months.
Xencor share price volatility
Over the last 12 months, Xencor's shares have ranged in value from as little as $19.355 up to $43.61. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Xencor's is 0.6157. This would suggest that Xencor's shares are less volatile than average (for this exchange).
Xencor, Inc. , a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression.
Xencor in the news
Xencor Appoints Nancy Valente, M.D., to Board of Directors
Frequently asked questionsWhat percentage of Xencor is owned by insiders or institutions?
Currently 0.789% of Xencor shares are held by insiders and 107.378% by institutions. How many people work for Xencor?
Latest data suggests 254 work at Xencor. When does the fiscal year end for Xencor?
Xencor's fiscal year ends in December. Where is Xencor based?
Xencor's address is: 111 West Lemon Avenue, Monrovia, CA, United States, 91016 What is Xencor's ISIN number?
Xencor's international securities identification number is: US98401F1057 What is Xencor's CUSIP number?
Xencor's Committee on Uniform Securities Identification Procedures number is: 98401F105
More guides on Finder
How to buy YanGuFang International Group (YGF) stock when it goes public
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
Ask an Expert